Alpha Teknova, Inc. (TKNO) Q1 2026 Earnings Call Transcript
Alpha Teknova, Inc. (TKNO) Q1 2026 Earnings Call Transcript
Seeking Alpha5/8/2026Neutral
TKNO
Alpha Teknova IncNASDAQHEALTHCAREDRUG MANUFACTURERS - SPECIALTY & GENERIC
Key Statistics
Market Cap
$291.12M
P/E Ratio
—
EPS
$-0.31
Beta
0.63
52W High
$6.68
52W Low
$1.91
50-Day MA
$4.43
200-Day MA
$4.01
Dividend Yield
—
Profit Margin
-41.10%
Forward P/E
—
PEG Ratio
—
About Alpha Teknova Inc
Alpha Teknova Inc (TKNO) is a prominent player in the synthetic biology sector, dedicated to producing essential biological reagents and supplements that support life sciences research and biomanufacturing. The company's innovative solutions are critical in high-demand applications such as vaccine development, cell and gene therapy, and diagnostic testing, reflecting its commitment to quality and exceptional customer service. With a strong biotechnology foundation and an emphasis on innovation, Alpha Teknova is strategically positioned to leverage growth opportunities in the dynamic life sciences market, making it an attractive investment for institutional investors.
Fundamentals
| Revenue (TTM) | $41.80M |
| Gross Profit (TTM) | $14.22M |
| EBITDA | $-9.47M |
| Operating Margin | -38.80% |
| Return on Equity | -23.90% |
| Return on Assets | -9.29% |
| Revenue/Share (TTM) | $0.78 |
| Book Value | $1.21 |
| Price-to-Book | 4.77 |
| Price-to-Sales (TTM) | 6.96 |
| EV/Revenue | 7.65 |
| EV/EBITDA | -6.23 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 13.10% |
| Shares Outstanding | $53.61M |
| Float | $10.88M |
| % Insiders | 9.32% |
| % Institutions | 84.72% |
Historical Volatility
HV 10-Day
65.77%
HV 20-Day
75.66%
HV 30-Day
103.08%
HV 60-Day
91.36%
HV Rank
98.8%
Volatility is currently contracting
Analyst Ratings
Consensus ($9.00 target)
4
Buy2
HoldLatest News
Teknova Reports First Quarter 2026 Financial Results
First quarter 2026 total revenue was $11.1 million, up 13% over the same quarter prior year Company reaffirms 2026 revenue guidance of $42-44 million
GlobeNewsWire5/6/2026Neutral
Teknova to Report First Quarter 2026 Financial Results on May 6, 2026
HOLLISTER, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the first quarter ended March 31, 2026, on Wednesday, May 6, 2026, following the close of market.
GlobeNewsWire4/22/2026Neutral
More HEALTHCARE Stocks
Data last updated: 7/9/2026